After 5-Year Winning Streak, Xarelto Makers Settle Personal Injury Suits
Bayer and Johnson & Johnson agree to resolve approximately 25,000 claims in federal and state courts for $775m, almost 13% of Xarelto's 2018 sales.
You may also be interested in...
Company is paying nearly $200m for an Oklahoma State University endowment, $12.5m to abate effects of opioid crisis and $60m for litigation costs.
Firms want Fifth Circuit to review whether federal law preempts failure-to-warn and design-defect claims; ruling in their favor could end 20,000-plus pending US cases.
Philadelphia jurors find that warnings of bleeding risk with Xarelto are adequate, giving companies 5-0 litigation score; sixth trial in June.